TY - JOUR
T1 - Building shared experience to advance practical application of pathway-based toxicology
T2 - Liver toxicity mode-of-action
AU - Willett, Catherine
AU - Rae, Jessica Caverly
AU - Goyak, Katy O.
AU - Minsavage, Gary
AU - Westmoreland, Carl
AU - Andersen, Melvin
AU - Avigan, Mark
AU - Duché, Daniel
AU - Harris, Georgina
AU - Hartung, Thomas
AU - Jaeschke, Hartmut
AU - Kleensang, Andre
AU - Landesmann, Brigitte
AU - Martos, Suzanne
AU - Matevia, Marilyn
AU - Toole, Colleen
AU - Rowan, Andrew
AU - Schultz, Terry
AU - Seed, Jennifer
AU - Senior, John
AU - Shah, Imran
AU - Subramanian, Kalyanasundaram
AU - Vinken, Mathieu
AU - Watkins, Paul
PY - 2014
Y1 - 2014
N2 - A workshop sponsored by the Human Toxicology Project Consortium (HTPC), 'Building Shared Experience to Advance Practical Application of Pathway-Based Toxicology: Liver Toxicity Mode-of-Action' brought together experts from a wide range of perspectives to inform the process of pathway development and to advance two prototype pathways initially developed by the European Commission Joint Research Center (JRC): liver-specific fibrosis and steatosis. The first half of the workshop focused on the theory and practice of pathway development; the second on liver disease and the two prototype pathways. Participants agreed pathway development is extremely useful for organizing information and found that focusing the theoretical discussion on a specific AOP is helpful. It is important to include several perspectives during pathway development, including information specialists, pathologists, human health and environmental risk assessors, and chemical and product manufacturers, to ensure the biology is well captured and end use is considered.
AB - A workshop sponsored by the Human Toxicology Project Consortium (HTPC), 'Building Shared Experience to Advance Practical Application of Pathway-Based Toxicology: Liver Toxicity Mode-of-Action' brought together experts from a wide range of perspectives to inform the process of pathway development and to advance two prototype pathways initially developed by the European Commission Joint Research Center (JRC): liver-specific fibrosis and steatosis. The first half of the workshop focused on the theory and practice of pathway development; the second on liver disease and the two prototype pathways. Participants agreed pathway development is extremely useful for organizing information and found that focusing the theoretical discussion on a specific AOP is helpful. It is important to include several perspectives during pathway development, including information specialists, pathologists, human health and environmental risk assessors, and chemical and product manufacturers, to ensure the biology is well captured and end use is considered.
KW - Adverse outcome pathways
KW - In vitro toxicology
KW - Liver toxicity
KW - Pathways of toxicity
KW - Systems toxicology
UR - http://www.scopus.com/inward/record.url?scp=84910635988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84910635988&partnerID=8YFLogxK
U2 - 10.14573/altex.1401281
DO - 10.14573/altex.1401281
M3 - Article
C2 - 24535319
AN - SCOPUS:84910635988
SN - 1868-596X
VL - 31
SP - 500
EP - 519
JO - ALTEX
JF - ALTEX
IS - 4
ER -